Please Wait.....
Report
Global Ovarian Cancer Drugs Market By Therapy (Chemotherapy, Targeted Therapy, Others), By Distribution Channel (Hospital Pharmacy, Drug Stores and Retail Pharmacy, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031
Market Report I 2022-10-01 I 189 Pages I Allied Market Research
The global ovarian cancer drugs market accounted for $2,283.8 million in 2021, and is expected to reach $5,063.59 million by 2031, registering a CAGR of 8.4% from 2022 to 2031.
Ovarian cancer is a growth of cells that forms in the ovaries. The cells multiply quickly and can invade and destroy healthy body tissue. The female reproductive system contains two ovaries, one on each side of the uterus. Each ovary, which is about the size of an almond, produces Egg (ova) along with the hormones progesterone and estrogen. Ovarian cancer treatment usually involves surgery and chemotherapy. Signs and symptoms of ovarian cancer may include abdominal bloating or swelling, quickly feeling full when eating, weight loss, discomfort in pelvic area, fatigue, back pain, changes in bowel habits and a frequent need to urinate.
It is estimated that ovarian cancer drugs market is expected to experience significant growth during the forecast period owing to increase in aging population of women, rise in prevalence of ovarian cancer, launch of innovative medications, boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D, presence of robust pipeline candidates, and increase in public awareness about the disease prevention in developing regions further facilitate the growth of the market. However, high cost of drug development and threat of failure are expected to impede the market growth. In contrast, advancement of cancer research and personalized medicine approach are factors that present new pathway in the industry are anticipated to provide significant growth opportunities for the ovarian cancer drugs market.
The ovarian cancer drugs market is segmented on the basis of therapy, distribution channel and region. Depending on therapy, the market is classified into chemotherapy, targeted therapy and others. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global ovarian cancer drugs market. The key companies profiled in the report include AbbVie, Pfizer, Inc., Merck Kagan, AstraZeneca, F. Hoffmann-La Roche AG, Johnson & Johnson Services, Inc., GlaxoSmithKline Plc, Boehringer Ingelheim International GmbH, Clovis Oncology, and Amgen.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global ovarian cancer drugs market analysis from 2021 to 2031 to identify the prevailing global ovarian cancer drugs market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the global ovarian cancer drugs market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global global ovarian cancer drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapy
- Chemotherapy
- Targeted Therapy
- Drug Class
- PARP Inhibitors
- Angiogenesis Inhibitors
- Others
- Others
By Distribution Channel
- Hospital Pharmacy
- Drug Stores and Retail Pharmacy
- Online Providers
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Abbvie Inc
- Pfizer, Inc.
- Merck KGaA
- AstraZeneca
- F. Hoffmann-La Roche AG
- Clovis Oncology
- Amgen Inc.
- Johnson & Johnson Services, Inc.
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY
4.1 Overview
4.1.1 Market size and forecast
4.2 Chemotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Targeted Therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.3.4 Targeted Therapy Global Ovarian Cancer Drugs Market by Drug Class
4.4 Others
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospital Pharmacy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Drug Stores and Retail Pharmacy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
5.4 Online Providers
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market share analysis by country
CHAPTER 6: GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Therapy
6.2.3 North America Market size and forecast, by Distribution Channel
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Therapy
6.2.4.1.3 Market size and forecast, by Distribution Channel
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Therapy
6.2.4.2.3 Market size and forecast, by Distribution Channel
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Therapy
6.2.4.3.3 Market size and forecast, by Distribution Channel
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Therapy
6.3.3 Europe Market size and forecast, by Distribution Channel
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Therapy
6.3.4.1.3 Market size and forecast, by Distribution Channel
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Therapy
6.3.4.2.3 Market size and forecast, by Distribution Channel
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Therapy
6.3.4.3.3 Market size and forecast, by Distribution Channel
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Therapy
6.3.4.4.3 Market size and forecast, by Distribution Channel
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Therapy
6.3.4.5.3 Market size and forecast, by Distribution Channel
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Therapy
6.3.4.6.3 Market size and forecast, by Distribution Channel
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Therapy
6.4.3 Asia-Pacific Market size and forecast, by Distribution Channel
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Therapy
6.4.4.1.3 Market size and forecast, by Distribution Channel
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Therapy
6.4.4.2.3 Market size and forecast, by Distribution Channel
6.4.4.3 Australia
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Therapy
6.4.4.3.3 Market size and forecast, by Distribution Channel
6.4.4.4 India
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Therapy
6.4.4.4.3 Market size and forecast, by Distribution Channel
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Therapy
6.4.4.5.3 Market size and forecast, by Distribution Channel
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Therapy
6.4.4.6.3 Market size and forecast, by Distribution Channel
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Therapy
6.5.3 LAMEA Market size and forecast, by Distribution Channel
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Therapy
6.5.4.1.3 Market size and forecast, by Distribution Channel
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Therapy
6.5.4.2.3 Market size and forecast, by Distribution Channel
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Therapy
6.5.4.3.3 Market size and forecast, by Distribution Channel
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Therapy
6.5.4.4.3 Market size and forecast, by Distribution Channel
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 F. Hoffmann-La Roche AG
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Johnson & Johnson Services, Inc.
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 GlaxoSmithKline Plc
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Boehringer Ingelheim International GmbH
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Clovis Oncology
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Abbvie Inc
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Pfizer, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Merck KGaA
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 AstraZeneca
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Amgen Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
LIST OF TABLES
TABLE 1. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 2. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 3. GLOBAL OVARIAN CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 5. GLOBAL OVARIAN CANCER DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 6. GLOBAL TARGETED THERAPY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DRUG CLASS, 2021-2031 (REVENUE, $MILLION)
TABLE 7. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 8. GLOBAL OVARIAN CANCER DRUGS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 9. GLOBAL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 10. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. GLOBAL OVARIAN CANCER DRUGS MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 12. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. GLOBAL OVARIAN CANCER DRUGS MARKET FOR DRUG STORES AND RETAIL PHARMACY, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 14. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 15. GLOBAL OVARIAN CANCER DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 16. GLOBAL OVARIAN CANCER DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 17. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 18. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 19. NORTH AMERICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 20. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 21. U.S. GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 23. CANADA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 29. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 31. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 32. FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 34. UK GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 35. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 36. ITALY GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 37. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 38. SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 40. REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 42. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 43. ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 44. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 45. JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 46. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 47. CHINA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 49. AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 50. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 51. INDIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 52. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 53. SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 54. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 55. REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 56. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 57. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 58. LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 59. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 60. BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 61. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 62. SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 63. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 65. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY THERAPY, 2021-2031 (REVENUE, $MILLION)
TABLE 66. REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67.F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
TABLE 68.F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS
TABLE 69.F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO
TABLE 70.F. HOFFMANN-LA ROCHE AG: NET SALES
TABLE 71.F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES
TABLE 72.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
TABLE 73.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
TABLE 74.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
TABLE 75.JOHNSON & JOHNSON SERVICES, INC.: NET SALES
TABLE 76.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES
TABLE 77.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 78.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 79.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 80.GLAXOSMITHKLINE PLC: NET SALES
TABLE 81.GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 82.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
TABLE 83.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OPERATING SEGMENTS
TABLE 84.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT PORTFOLIO
TABLE 85.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: NET SALES
TABLE 86.BOEHRINGER INGELHEIM INTERNATIONAL GMBH: KEY STRATERGIES
TABLE 87.CLOVIS ONCOLOGY: COMPANY SNAPSHOT
TABLE 88.CLOVIS ONCOLOGY: OPERATING SEGMENTS
TABLE 89.CLOVIS ONCOLOGY: PRODUCT PORTFOLIO
TABLE 90.CLOVIS ONCOLOGY: NET SALES
TABLE 91.CLOVIS ONCOLOGY: KEY STRATERGIES
TABLE 92.ABBVIE INC: COMPANY SNAPSHOT
TABLE 93.ABBVIE INC: OPERATING SEGMENTS
TABLE 94.ABBVIE INC: PRODUCT PORTFOLIO
TABLE 95.ABBVIE INC: NET SALES
TABLE 96.ABBVIE INC: KEY STRATERGIES
TABLE 97.PFIZER, INC.: COMPANY SNAPSHOT
TABLE 98.PFIZER, INC.: OPERATING SEGMENTS
TABLE 99.PFIZER, INC.: PRODUCT PORTFOLIO
TABLE 100.PFIZER, INC.: NET SALES
TABLE 101.PFIZER, INC.: KEY STRATERGIES
TABLE 102.MERCK KGAA: COMPANY SNAPSHOT
TABLE 103.MERCK KGAA: OPERATING SEGMENTS
TABLE 104.MERCK KGAA: PRODUCT PORTFOLIO
TABLE 105.MERCK KGAA: NET SALES
TABLE 106.MERCK KGAA: KEY STRATERGIES
TABLE 107.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 108.ASTRAZENECA: OPERATING SEGMENTS
TABLE 109.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 110.ASTRAZENECA: NET SALES
TABLE 111.ASTRAZENECA: KEY STRATERGIES
TABLE 112.AMGEN INC.: COMPANY SNAPSHOT
TABLE 113.AMGEN INC.: OPERATING SEGMENTS
TABLE 114.AMGEN INC.: PRODUCT PORTFOLIO
TABLE 115.AMGEN INC.: NET SALES
TABLE 116.AMGEN INC.: KEY STRATERGIES
LIST OF FIGURES
FIGURE 1.GLOBAL OVARIAN CANCER DRUGS MARKET SEGMENTATION
FIGURE 2.GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031
FIGURE 3.GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031
FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
FIGURE 5.PORTER FIVE-1
FIGURE 6.PORTER FIVE-2
FIGURE 7.PORTER FIVE-3
FIGURE 8.PORTER FIVE-4
FIGURE 9.PORTER FIVE-5
FIGURE 10.TOP PLAYER POSITIONING
FIGURE 11.GLOBAL OVARIAN CANCER DRUGS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 12.GLOBAL OVARIAN CANCER DRUGS MARKET,BY THERAPY,2021(%)
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CHEMOTHERAPY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TARGETED THERAPY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 16.GLOBAL OVARIAN CANCER DRUGS MARKET,BY DISTRIBUTION CHANNEL,2021(%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031(%)
FIGURE 20.GLOBAL OVARIAN CANCER DRUGS MARKET BY REGION,2021
FIGURE 21.U.S. GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 22.CANADA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 23.MEXICO GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 24.GERMANY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 25.FRANCE GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 26.UK GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 27.ITALY GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 28.SPAIN GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 29.REST OF EUROPE GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 30.JAPAN GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 31.CHINA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 32.AUSTRALIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 33.INDIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 34.SOUTH KOREA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 35.REST OF ASIA-PACIFIC GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 36.BRAZIL GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 37.SAUDI ARABIA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 38.SOUTH AFRICA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 39.REST OF LAMEA GLOBAL OVARIAN CANCER DRUGS MARKET,2021-2031($MILLION)
FIGURE 40. TOP WINNING STRATEGIES, BY YEAR
FIGURE 41. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 42. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 43.PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 44.COMPETITIVE DASHBOARD
FIGURE 45.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
FIGURE 46.F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)
FIGURE 47.JOHNSON & JOHNSON SERVICES, INC..: NET SALES ($MILLION)
FIGURE 48.GLAXOSMITHKLINE PLC.: NET SALES ($MILLION)
FIGURE 49.BOEHRINGER INGELHEIM INTERNATIONAL GMBH.: NET SALES ($MILLION)
FIGURE 50.CLOVIS ONCOLOGY.: NET SALES ($MILLION)
FIGURE 51.ABBVIE INC.: NET SALES ($MILLION)
FIGURE 52.PFIZER, INC..: NET SALES ($MILLION)
FIGURE 53.MERCK KGAA.: NET SALES ($MILLION)
FIGURE 54.ASTRAZENECA.: NET SALES ($MILLION)
FIGURE 55.AMGEN INC..: NET SALES ($MILLION)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security